Trial Profile
An Open Phase I Single Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck With Repeated Administration in Patients With Clinical Benefit
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Oct 2014
Price :
$35
*
At a glance
- Drugs Bivatuzumab mertansine (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 08 Oct 2014 New trial record